Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature

BACKGROUND: Nivolumab is an immune checkpoint inhibitor targeting programmed death-1 protein and has been approved for the treatment of multiple advanced malignancies. Adverse effects of immune checkpoint inhibitors are distinct from conventional cytotoxic chemotherapy and can be life-threatening if...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaheen, Shagufta, Mirshahidi, Hamid, Nagaraj, Gayathri, Hsueh, Chung-Tsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941729/
https://www.ncbi.nlm.nih.gov/pubmed/29761026
http://dx.doi.org/10.1186/s40164-018-0104-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5941729/
https://www.ncbi.nlm.nih.gov/pubmed/29761026
http://dx.doi.org/10.1186/s40164-018-0104-y

Ejemplares similares